Advanced Filters
noise

All Participating Sites, Germany Clinical Trials

A listing of All Participating Sites, Germany clinical trials actively recruiting patients volunteers.

Found 65,259 clinical trials
S Sven Behrendt, MD

Sterile Allogeneic Spongioflex® Allograft as Partial Meniscal Replacement After Incomplete Meniscal Loss

The goal of this clinical trial is to learn if partial meniscal replacement can prevent or postpone total meniscal replacement, in adult patients (female/male) with partial meniscal loss. The main questions it aims to answer are: Can partial meniscal replacement improve knee function? Can partial meniscal replacement prevent/postpone total meniscal …

18 - 60 years of age All Phase N/A
L Lise Beumeler, Dr.

Hand and Arm Rehabilitation Using VR

Patients admitted to the ICU due to critical illness often experience physical, mental, cognitive, or social issues. Research indicates that inadequate physical recovery is associated with lower handgrip strength, and hand function in ICU patients is lower compared to healthy individuals. To address this, a Virtual Reality (VR) exergame was …

18 years of age All Phase N/A
W Wellington F Silva, MD PhD

Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia

This is a interventional phase II study aiming to examine the complete response rate of a bortezomib-based salvage regimen in adults with refractory or relapsed acute lymphoblastic leukemia (ALL), seeking to compare outcomes with the available literature and with our historical data on relapsed/refractory ALL.

16 - 60 years of age All Phase 2

Outcomes and Cosmesis With Whole Breast Irradiation and Boost

This study is being done to evaluate cosmetic, patient-reported outcome measures (PROMs), and toxicities for women undergoing ultra-short whole breast irradiation (WBI) therapy with simultaneous integrated boost (SIB). 50 participants will be on study for up to 60 months.

18 years of age Female Phase N/A
H Haojun Chen, PhD

Clinical Evaluation of 177Lu-AB-3PRGD2 in Various Solid Tumors With Integrin αvβ3 Positive Expression

This is an open-label, non-controlled, non-randomized study to assess the therapeutic efficacy of 177Lu-AB-3PRGD2 in patients with various solid tumors who will undergo radioligand therapy using 177Lu-AB-3PRGD.

18 - 90 years of age All Phase 1
J Jun Huang, MD

Dynamic Multi-omics Integration Model to Predict Neoadjuvant Therapy Response in Locally Advanced Rectal Cancer

The goal of this observational study is to establish a dynamic multi-omics integration model for predicting pathological complete response (pCR) after neoadjuvant treatment in locally advanced (T3-4NxM0) rectal cancer, providing support for subsequent patient selection for the watch-and-wait strategy. The main question it aims to answer is: What is the …

18 - 80 years of age All Phase N/A
L Lin Liu, Professor

Clinical Study on Modified Allogeneic Hematopoietic Stem Cell Transplantation Regimen for Severe Aplastic Anemia

The aim of this study was to evaluate the safety and efficacy of a modified allogeneic hematopoietic stem cell transplantation regimen for aplastic anemia.

3 - 65 years of age All Phase 2
J Jianhong Peng, Doctor

Modified Sandwich Therapeutic Regimen for Locally Advanced Rectal Cancer

In the treatment of locally advanced rectal cancer, the short-term and long-term efficacy of the traditional sandwich regimen has not reached satisfactory efficacy. For this reason, the concept of reducing the dose of postoperative chemotherapy or directly moving forward the full amount of postoperative chemotherapy was proposed, which is called …

18 - 75 years of age All Phase 2
P Projets PARC

Kinetics of Urinary Excretion of Gadolinium Contrast Agents Used in MRI Examinations

This is a single-center cohort study aimed to describe the urinary excretion kinetics of gadolinium contrast agents (Gd-CAs). Patients with a prescription for injected MRI are invited to participate in the study. If they agree, blood and urine samples are collected before Gd-CAs injection, and urine samples are collected between …

18 years of age All Phase N/A
K Karen Moody, MD

Iscador® P (Mistletoe) Immunotherapy for Recurrent Osteogenic Sarcoma

This will be a phase II, single arm study of osteosarcoma patients with fully resected pulmonary metastases. The MTD corresponds to the dosage recommendations of the manufacturer of Iscador® P which is licensed in Sweden, New Zealand, South Korea, Germany and Switzerland for the treatment of solid tumors and precancerous …

8 - 30 years of age All Phase 2

Simplify language using AI